Ottimo Pharma
Ling Zeng has extensive legal experience in the pharmaceutical sector, currently serving as GC & EVP Execution at Ottimo Pharma since October 2024. Prior roles include Chief Legal and Administrative Officer at Omega Therapeutics and Chief Legal Officer & Secretary at Dicerna Pharmaceuticals. Ling Zeng has also held significant positions at Novartis, Bausch Health Companies, Penwest Pharmaceuticals, and Barr Pharmaceuticals, focusing on M&A, corporate governance, compliance, and regulatory issues. Ling Zeng began a legal career at Cleary Gottlieb Steen & Hamilton LLP and initially worked as a research scientist at Alkermes. Ling Zeng holds a JD from Georgetown University Law Center, an M.S. in BioPhysics from Brandeis University, and a BS in Physics from Peking University.
This person is not in any teams
This person is not in any offices
Ottimo Pharma
Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.